A Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of 24 Hour and 72 Hour Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease
Phase of Trial: Phase I
Latest Information Update: 19 Nov 2019
Price : $35 *
At a glance
- Drugs Levodopa/carbidopa (Primary) ; Levodopa/carbidopa
- Indications Parkinson's disease
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors AbbVie
- 13 Nov 2019 Status changed from recruiting to completed.
- 30 Apr 2019 According to the AbbVie media release, data from this trial will be presented at the American Academy of Neurology Annual Meeting 2019.
- 13 Mar 2019 Planned End Date changed from 25 Feb 2019 to 28 Jun 2019.